Skip to main content
IRIX
NASDAQ Life Sciences

Iridex Reports Q4 Net Loss of $200K, Sets FY Revenue Outlook at $51-53M

feedReported by Reuters
Sentiment info
Negative
Importance info
7
Price
$1.36
Mkt Cap
$23.206M
52W Low
$0.79
52W High
$1.648
Market data snapshot near publication time

summarizeSummary

IRIDEX Corporation announced its fourth-quarter results, reporting revenue of $14.7 million and a net loss of $200 thousand. The company also provided a full-year revenue outlook of $51-53 million. These financial figures, particularly the net loss, are crucial for investors to assess the company's recent performance and future trajectory. This earnings update is a distinct event from the recent 8-K filing regarding a new corporate headquarters lease. Traders will closely monitor how these results align with market expectations and the company's ability to meet its forward guidance.

At the time of this announcement, IRIX was trading at $1.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.2M. The 52-week trading range was $0.79 to $1.65. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.


show_chartPrice Chart

Share this article

Copied!

feed IRIX - Latest Insights

IRIX
Apr 07, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
IRIX
Apr 02, 2026, 4:20 PM EDT
Filing Type: 10-K
Importance Score:
8
IRIX
Mar 26, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
8
IRIX
Mar 26, 2026, 4:05 PM EDT
Source: Reuters
Importance Score:
7
IRIX
Mar 13, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
8
IRIX
Jan 12, 2026, 9:11 AM EST
Filing Type: 8-K
Importance Score:
8
IRIX
Jan 08, 2026, 4:33 PM EST
Filing Type: 4
Importance Score:
7
IRIX
Jan 08, 2026, 4:28 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
9